Medigene AG (NMarkt: MDG) is a publicly quoted German biopharmaceutical company with Headquarters in Martinsried, Munich, and a subsidiary, Medigene Inc. in San Diego, California. MediGene combines a broad technology platform with products in pre-clinical and clinical development. The company has built up core competence in cardiac and cancer diseases. Founded in 1994, MediGene now has 150 employees (as of December 1, 2001) of which about 80% work in R&D. Around 50% are scientists with a Ph.D.degree.
The Company’s multi-tiered business strategy has generated a number of proprietary enabling technologies to create a portfolio of novel therapeutic opportunities and drug candidates for in-house development and out-licensing.
Based on its successful research work, MediGene has so far developed five fundamental, patented platform technologies. The ITD, CVLP, AAV, HSV and amplicon technologies are the foundation for the development of novel drugs that target the cause of diseases, a resource that can supply the Company’s product pipeline - and those of potential pharmaceutical partners - with new development projects.
Seven products are currently in clinical trials and registration process, the first product launches are expected for 2003. In addition, the product portfolio is to be complemented through strategic in-licensing and potential acquisitions of companies with a strategic fit and complementary technologies.
| Contact Details: |
| Lochhamer Strasse 11 |
| Martinsried |
| Bavaria |
| D-82152 |
| Germany |
| Tel: | 49 89 89 56 32 0 |
| Fax: | 49 89 89 56 32 20 |
| Email: | |
| WWW: | www.medigene.de/
|
| |
Recent Publications by MediGene AG: |  |
Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry.
Naturally selected T-cell receptors (TCRs) are characterised by low... | 6th December, 2007
| Avidex Limited (subsidiary of Medigene Ag), 57c Milton Park, Abingdon,
| Protein Eng Des Sel. 2007 Aug;20(8):397-403. Epub 2007 Jul 20.
DOI Direct Link |
Laminar order within Langmuir-Blodgett multilayers from phospholipid and myelin basic protein: a neutron reflectivity study.
Multilayers consisting of negatively charged phospholipid DMPA and myelin... | 3rd October, 2007
| Medigene
| Langmuir. 2007 Jul 31;23(16):8491-6. Epub 2007 Jul 6.
DOI Direct Link |
Extraction and quantification of the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane from human plasma.
Multilayers consisting of negatively charged phospholipid DMPA and myelin... | 26th May, 2007
| MediGene AG, 82152 Martinsried, Germany.
| Anal Biochem. 2007 Apr 1;363(1):157-9. Epub 2007 Jan 26.
DOI Direct Link |
Emerging therapeutic targets in chronic heart failure: part II.
Chronic heart failure is characterised by functional deficiencies of the... | 2nd May, 2006
| Department of Research, MediGene AG, Martinsried, Germany.
| Expert Opin Ther Targets. 2003 Feb;7(1):49-59.
DOI Direct Link |
A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir.
BACKGROUND: The dogma in psoriasis is that due to pathogen-induced... | 4th February, 2006
| Medigene AG, Lochhamerstrasse 11, 82152 Martinsried, Germany.
| Br J Dermatol. 2005 Nov;153(5):937-44.
DOI Direct Link |
→View more MediGene AG research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 384 times since April 2007, the link to the organisation's website has been followed 62 times
Recent Search Terms used to find this page: MediGene aav | medigene psoriasis | medigene ag etomoxir | medigene cvlp patent | medigene l1 | medigene | .
Search for more companies in Martinsried
Search for more companies in Bavaria
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
MediGene AG
